Phaseline

Companies › Nutshell Therapeutics (Shanghai)

Nutshell Therapeutics (Shanghai): clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NTS071
TP53 Y220C mutant stabilizer
TP53Phase 1Advanced Solid TumorsDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07060989NTS071Phase 1Advanced Solid TumorsOncologyDec 2028

Targets

TP53 (1)

Companies with the same targets

SynerGene Therapeutics PMV Pharmaceuticals Kartos Therapeutics Precigen OSE Immunotherapeutics Changchun GeneScience Pharmaceutical Jacobio Pharmaceuticals Clasp Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.